IASO Biotechnology's Fucaso Therapy Receives BLA Approval for Advanced Multiple Myeloma Treatment IASO Bio's Fucaso therapy, approved by Hong Kong's Department of Health, treats relapsed multiple myeloma. This marks a significant milestone for China-developed therapies.

IASO Biotechnology's Fucaso Therapy Receives BLA Approval for Advanced Multiple Myeloma Treatment #China #Hong_Kong #CAR-T_therapy #IASO_Bio #FUCASO

IASO Bio Showcases Impressive Three-Year Results of CAR-T Therapy for Multiple Myeloma at IMS 2025 IASO Bio revealed notable three-year follow-up findings for its CAR-T therapy, Fucaso, for treating multiple myeloma at the 2025 IMS Annual Meeting, showing strong long-term efficacy.

IASO Bio Showcases Impressive Three-Year Results of CAR-T Therapy for Multiple Myeloma at IMS 2025 #China #Shanghai #CAR-T_therapy #IASO_Bio #FUCASO

IASO Bio’s Equecabtagene Autoleucel Secures Regulatory Green Light in Hong Kong IASO Biotherapeutics has received acceptance for its New Drug Application for Equecabtagene Autoleucel, a CAR-T therapy for relapsed multiple myeloma, from Hong Kong health authorities.

IASO Bio’s Equecabtagene Autoleucel Secures Regulatory Green Light in Hong Kong #China #Hong_Kong #CAR-T_therapy #IASO_Bio #FUCASO

IASO Bio's New Drug Application Acceptance Marks Milestone for FUCASO in Singapore IASO Bio's Equecabtagene Autoleucel (FUCASO) receives NDA acceptance from Singapore's HSA, marking a significant step in CAR-T therapy expansion.

IASO Bio's New Drug Application Acceptance Marks Milestone for FUCASO in Singapore #Singapore #IASO_Bio #Equecabtagene #FUCASO